| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BI-2536 | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | QS11 | GDSC1000 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | YM201636 | GDSC1000 | pan-cancer | AAC | -0.0092 | 0.8 |
| mRNA | NVP-BEZ235 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.8 |
| mRNA | compound 1B | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | PF-562271 | GDSC1000 | pan-cancer | AAC | 0.0097 | 0.8 |
| mRNA | tandutinib | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0093 | 0.8 |
| mRNA | SB590885 | GDSC1000 | pan-cancer | AAC | -0.0089 | 0.8 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | 0.014 | 0.8 |